GILD241206C81000
- 13.25
- 0.000.00%
Gilead Sciences Newsroom
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target
Gilead Sciences Hits 4-week High
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Gilead Sciences (GILD) Receives a Buy From Jefferies
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $105 to $125
Today's Analyst Rating | Broadcom Price Target Raised to $205 by Citi, Oracle Price Target Raised to $210 by UBS
Dec 11, Wall Street analysts have updated their stock ratings today including $Broadcom(AVGO.US)$ and $Oracle(ORCL.US)$.
Express News | Gilead : Leerink Partners Raises Target Price to $99 From $96
Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Oppenheimer raised the Target Price of Gilead Sciences to $115.
Gelonghui December 11 | Oppenheimer: Increased the Target Price for Gilead Sciences from $105 to $115, maintaining an "Outperform" rating. (Gelonghui)
BofA Restarts Coverage of 11 Large-cap Biopharmas
Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3
EST Dec 10th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Citi Remains a Buy on Gilead Sciences (GILD)
Express News | Bank of America Merrill Lynch resumes coverage of Gilead Sciences with a rating of Buy.
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Gilead Sciences Analyst Ratings
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105